• Explore /
  • Poster
  • / Final results of a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab combination treatment in patients with stage IIIB-IV unresectable or metastatic melanoma.

Final results of a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab combination treatment in patients with stage IIIB-IV unresectable or metastatic melanoma.

Abstract Poster

Authors

null

Robert Hans Ingemar Andtbacka

Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT

Robert Hans Ingemar Andtbacka , Merrick I. Ross , Sanjiv S. Agarwala , Matthew H. Taylor , John T. Vetto , Rogerio Izar Neves , Adil Daud , Hung T. Khong , Richard S. Ungerleider , Maki Tanaka , Kenneth F. Grossmann

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT02272855

Citation

J Clin Oncol 35, 2017 (suppl; abstr 9510)

DOI

10.1200/JCO.2017.35.15_suppl.9510

Abstract #

9510

Poster Bd #

118

Abstract Disclosures

Similar Posters

First Author: Robert Hans Ingemar Andtbacka

First Author: Inge Marie Svane

First Author: Minsuk Kwon

First Author: Zhi Peng